Microplasmin (synthetic Human)
Microplasmin (synthetic Human) Uses, Dosage, Side Effects, Food Interaction and all others data.
Microplasmin (synthetic Human) is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Microplasmin (synthetic Human) is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
Trade Name | Microplasmin (synthetic Human) |
Generic | Ocriplasmin |
Ocriplasmin Other Names | Microplasmin, Microplasmin (synthetic human), Ocriplasmin, Ocriplasmina, Recombinant human microplasmin |
Type | |
Formula | C1214H1890N338O348S14 |
Weight | 27250.0 Da |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Microplasmin (synthetic Human) is a proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula.
Microplasmin (synthetic Human) is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
Microplasmin (synthetic Human) is also used to associated treatment for these conditions: Symptomatic Vitreomacular Adhesion
How Microplasmin (synthetic Human) works
Microplasmin (synthetic Human) has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).
Toxicity
The most commonly reported reactions (≥ 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.
Food Interaction
No interactions found.Elimination Route
Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL
Innovators Monograph
You find simplified version here Microplasmin (synthetic Human)